Stefan Schreiber, ECCO 2021: Risankizumab – an Induction Therapy for Crohn’s Disease
We were delighted to catch up with Professor Stefan Schreiber (University Hospital Schleswig-Holstein, Kiel, Germany) to discuss the results from the phase 3 ADVANCE and MOTIVATE studies, investigating risankizumab as an induction therapy in patients with moderate-to-severe Crohn’s Disease.
The abstract ‘Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies‘ (OP26) was presented at the 16th Congress of ECCO, July 2-3 & 8-10, 2021, Virtual.
- What is the rationale for the use of risankizumab as an induction therapy in patients with moderate-to-severe Crohn’s Disease (CD)? (0:15)
- Could you give us a brief overview of the ADVANCE and MOTIVATE studies, and what were the efficacy, safety and tolerability findings? (2:22)
Disclosures: Stefan Schreiber reports personal fees from Abbvie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, provention Bio, Protagonist, Galapagos and Falk.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ECCO 2021 (Virtual).
Share this Video
Related Videos In Digestive Disorders
QUASAR: phase 3 study of guselkumab in moderately to severely active ulcerative colitis: Jessica Allegretti, DDW 2023
The QUASAR Phase 3 Induction Study (NCT04033445) investigated the efficacy and safety of the IL-23 p19 subunit antagonist guselkumab in the treatment of moderately to severely active ulcerative colitis. We caught up with Dr Jessica Allegretti (Brigham and Women’s Hospital, Boston, MA, USA), to discuss the aims, design and inclusion criteria of the QUASAR Phase […]
Guselkumab: an investigational monoclonal antibody for ulcerative colitis: Jessica Allegretti, DDW 2023
Guselkumab is a fully human monoclonal antibody IL-23 p19 subunit antagonist currently being investigated in hard to treat, moderately to severely active ulcerative colitis. We were delighted to speak with Dr Jessica Allegretti, (Brigham and Women’s Hospital, Boston, MA, USA) around the burden of ulcerative colitis in patients with inadequate response to currently approved treatments, […]
UEG Digestive Health Month: Matthias Löhr, May 2023
Digestive Health Month took place over May 2023 to raise awareness of digestive diseases and cancers, which often remain overlooked in terms of policy, funding and research in Europe. We were delighted to talk with UEG’s Vice President Prof. Matthias Löhr (Karolinska Institutet, Stockholm, Sweden) around the public health and economic burden of digestive diseases, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!